Bryan G. Johnson

5.8k total citations · 1 hit paper
59 papers, 4.6k citations indexed

About

Bryan G. Johnson is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Materials Chemistry. According to data from OpenAlex, Bryan G. Johnson has authored 59 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Cellular and Molecular Neuroscience, 42 papers in Molecular Biology and 7 papers in Materials Chemistry. Recurrent topics in Bryan G. Johnson's work include Neuroscience and Neuropharmacology Research (49 papers), Receptor Mechanisms and Signaling (30 papers) and Ion channel regulation and function (17 papers). Bryan G. Johnson is often cited by papers focused on Neuroscience and Neuropharmacology Research (49 papers), Receptor Mechanisms and Signaling (30 papers) and Ion channel regulation and function (17 papers). Bryan G. Johnson collaborates with scholars based in United States, United Kingdom and Spain. Bryan G. Johnson's co-authors include Darryle D. Schoepp, James A. Monn, Rebecca A. Wright, Craig R. Salhoff, Nancy G. Mayne, J. Paul Burnett, Paul L. Ornstein, Joseph P. Tizzano, Rama M. Belagaje and Stephen Baker and has published in prestigious journals such as Nature Medicine, Pain and Neuroscience.

In The Last Decade

Bryan G. Johnson

58 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

2007 790 citations Bryan G. Johnson, James A. Monn et al. profile →

Peers

Countries citing papers authored by Bryan G. Johnson

Since Specialization

Citations

This map shows the geographic impact of Bryan G. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan G. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan G. Johnson more than expected).

Fields of papers citing papers by Bryan G. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan G. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan G. Johnson. The network helps show where Bryan G. Johnson may publish in the future.

Co-authorship network of co-authors of Bryan G. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan G. Johnson. A scholar is included among the top collaborators of Bryan G. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan G. Johnson. Bryan G. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vitro and in Vivo Evidence for a Lack of Interaction with Dopamine D2 Receptors by the Metabotropic Glutamate 2/3 Receptor Agonists 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-bicaroxylate Monohydrate (LY354740) and (−)-2-Oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic Acid (LY379268) 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Matthew Fell, Kenneth W. Perry, Julie F. Falcone, Bryan G. Johnson, Vanessa Barth, Karen Rash, Virginia L. Lucaites, Penny G. Threlkeld, James A. Monn, David L. McKinzie, Gerard J. Marek, Kjell Svensson, David L. Nelson	31
2	Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge 2009 ·Neuropharmacology ·Matthew Fell, Jason Katner, Bryan G. Johnson, Albert Khilevich, Jeffrey M. Schkeryantz, Kenneth W. Perry, Kjell Svensson	28
3	The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment Emergent Catalepsy: Implications for the Treatment of Extrapyramidal Symptoms 2006 ·Schizophrenia Bulletin ·K. Rasmussen, M.-A. Hsu, Sally Noone, Bryan G. Johnson, (unknown), Susan K. Hemrick-Luecke	14
4	Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor 2002 ·Neuropharmacology ·A. Linden, Bryan G. Johnson, Steven Peters, H E Shannon, (unknown), (unknown), (unknown), Anja Köster, M Baez, Darryle D. Schoepp	83
5	Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats 2002 ·Pharmacology Biochemistry and Behavior ·Matthew Clark, Bryan G. Johnson, Rebecca A. Wright, James A. Monn, Darryle D. Schoepp	27
6	Evaluation of the activity of a novel metabotropic glutamate receptor antagonist (±)-2-amino-2-(3-cis and trans-carboxycyclobutyl-3-(9-thioxanthyl)propionic acid) in the in vitro neonatal spinal cord and in an in vivo pain model 1999 ·Neuroscience ·(unknown), (unknown), Emanuele Sher, Barry P. Clark, Mary Jeanne Kallman, Rebecca A. Wright, Bryan G. Johnson, Darryle D. Schoepp, Ann E. Kingston	23
7	Group III human metabotropic glutamate receptors 4, 7 and 8: Molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells 1998 ·Molecular Brain Research ·(unknown), Rebecca A. Wright, (unknown), Stanley G. Burgett, Jeffrey S. Arnold, Paul R. Rosteck, Bryan G. Johnson, Darryle D. Schoepp, Rama M. Belagaje	88
8	Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist 1998 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. Wright, Craig R. Salhoff, James A. Monn	19
9	Synthesis and metabotropic glutamate receptor antagonist activity of N1-substituted analogs of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acid 1998 ·Bioorganic & Medicinal Chemistry Letters ·Matthew J. Valli, Darryle D. Schoepp, Rebecca A. Wright, Bryan G. Johnson, Ann E. Kingston, Rosemarie Tomlinson, James A. Monn	11
10	2,3′-disubstituted-2-(2′-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors 1998 ·Bioorganic & Medicinal Chemistry Letters ·Iván Collado, Jesús Ezquerra, Ángel Mazón, Concepción Pedregal, (unknown), Anne Kingston, (unknown), Rebecca A. Wright, Bryan G. Johnson, Darryle D. Schoepp	10
11	LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors 1997 ·Neuropharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. Wright, Craig R. Salhoff, Nancy G. Mayne, Sheng‐Nan Wu, Sandra L. Cockerham, J. Paul Burnett, (unknown), David Bleakman, James A. Monn	193
12	The Novel Metabotropic Glutamate Receptor Agonist 2 R ,4 R -APDC Potentiates Stimulation of Phosphoinositide Hydrolysis in the Rat Hippocampus by 3,5-dihydroxyphenylglycine: Evidence for a Synergistic Interaction Between Group 1 and Group 2 Receptors 1996 ·Neuropharmacology ·Darryle D. Schoepp, Craig R. Salhoff, Rebecca A. Wright, Bryan G. Johnson, J. Paul Burnett, Nancy G. Mayne, Rama M. Belagaje, Song Wu, James A. Monn	88
13	Second-messenger responses in brain slices to elucidate novel glutamate receptors 1995 ·Journal of Neuroscience Methods ·Darryle D. Schoepp, Bryan G. Johnson, Craig R. Salhoff, Rebecca A. Wright, John Goldsworthy, Stephen Baker	21
14	Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate 1995 ·Neuropharmacology ·Darryle D. Schoepp, Bryan G. Johnson, Craig R. Salhoff, (unknown), Manisha Desai, J. Paul Burnett, Nancy G. Mayne, James A. Monn	65
15	Disruption of Potential α‐Helix in the G Loop of the Guinea: Pig 5‐Hydroxytryptamine₂Receptor Does Not Prevent Receptor Coupling to Phosphoinositide Hydrolysis 1994 ·Journal of Neurochemistry ·Stephanie W. Watts, Marlene L. Cohen, (unknown), Bryan G. Johnson, Darryle D. Schoepp, Melvyn Baez	9
16	3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity 1993 ·Journal of Medicinal Chemistry ·Charles H. Mitch, J. David Leander, Laurane G. Mendelsohn, Walter N. Shaw, David T. Wong, Buddy E. Cantrell, Bryan G. Johnson, (unknown), (unknown)	50
17	Metabotropic glutamate receptor modulation of cAMP accumulation in the neonatal rat hippocampus 1993 ·Neuropharmacology ·Darryle D. Schoepp, Bryan G. Johnson	36
18	Inhibition of Cyclic AMP Formation by a Selective Metabotropic Glutamate Receptor Agonist 1992 ·Journal of Neurochemistry ·Darryle D. Schoepp, Bryan G. Johnson, James A. Monn	140
19	Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)- and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis 1991 ·European Journal of Pharmacology Molecular Pharmacology ·Darryle D. Schoepp, Bryan G. Johnson, (unknown), James A. Monn	76
20	In Vitro and In Vivo Pharmacology of trans‐ and cis‐(±)‐1‐Amino‐1,3‐Cyclopentanedicarboxylic Acid: Dissociation of Metabotropic and Ionotropic Excitatory Amino Acid Receptor Effects 1991 ·Journal of Neurochemistry ·(unknown), Bryan G. Johnson, Craig R. Salhoff, John W. McDonald, Michael V. Johnston	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact